Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA is positive~* Genotype 6~* Treatment naive~* Raised ALT~Exclusion Criteria:~* Active substance abuse~* Poorly controlled psychiatric disease~* HBsAg positive~* Anti-HIV positive~* Suffering from other significant concurrent medical conditions including chronic liver diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 24-Week treatment group (Type: EXPERIMENTAL): Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
- 48-Week treatment group (Type: ACTIVE_COMPARATOR): Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).